BTMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Biote Corp (BTMD) is not a good buy for a beginner investor with a long-term strategy at this time. The stock is facing significant financial challenges, bearish technical indicators, and a lack of strong catalysts for growth. Although insider buying is a positive signal, the overall sentiment and performance do not align with the user's investment goals.
The technical indicators are bearish. The MACD is negative and expanding downward, the RSI is neutral but leaning towards oversold territory, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot level of 1.49, with key support at 1.362 and resistance at 1.617.
Insider buying has increased significantly by 221.99% over the last month, indicating some confidence from insiders.
The company's Q4 financials showed a decline in revenue (-6.87% YoY), net income (-47.23% YoY), EPS (-50.00% YoY), and gross margin (-4.59% YoY). Analysts have lowered price targets, citing challenges with clinic acquisition, attrition management, and the impact of a voluntary recall. The stock is also range-bound due to uncertainty in planned operating expenditure investments.
In Q4 2025, Biote Corp reported declining financial metrics across the board. Revenue dropped to $46.41M (-6.87% YoY), net income fell to $1.95M (-47.23% YoY), and EPS decreased to $0.05 (-50.00% YoY). Gross margin also declined to 68.03% (-4.59% YoY), reflecting operational inefficiencies.
Analysts have lowered price targets across the board. B. Riley reduced the target to $2 (Neutral), Roth Capital to $3 (Buy), TD Cowen to $2.50 (Buy), and Truist to $5 (Buy). Analysts highlight ongoing challenges, including a voluntary recall and slow clinic acquisition, but some see potential for growth resuming in the second half of 2026.
